Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01040208 · ClinicalTrials.gov registry record · Phase 3
12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress
A Phase 3 study, sponsored by Sprout Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 111
- Enrollment target
NCT01040208 is a Phase 3 study that was terminated before completion, run by Sprout Pharmaceuticals. The registered enrollment target is 111 participants.
The verdict
NCT01040208, a Phase 3 study, was terminated before completion, sponsored by Sprout Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 111 participants
- Enrollment target
Study Summary
The current trial will explore the safety of flibanserin in combination with Selective Serotonin Reuptake Inhibitors or Norepinephrine Serotonin Reuptake Inhibitors in a representative population of women with depressive and possible concurrent anxiety symptomatology.
Interventions
- DRUG flibanserin 50 mg to 100 mg qhs
- DRUG flibanserin 100 mg qhs
- DRUG placebo 2 tablets qhs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01040208
The ClinicalTrials.gov registry entry for NCT01040208 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sprout Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which flibanserin 50 mg to 100 mg qhs is the first listed.
NCT01040208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01040208 about?
NCT01040208 is a clinical study titled "12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress". The current trial will explore the safety of flibanserin in combination with Selective Serotonin Reuptake Inhibitors or Norepinephrine Serotonin Reuptake Inhibitors in a representative population of women with depressive and possible concurrent anxiety symptomatology.
What is the current status of trial NCT01040208?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 111 participants. The study started on 2010-01. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01040208?
The interventions under investigation include: flibanserin 50 mg to 100 mg qhs (DRUG), flibanserin 100 mg qhs (DRUG), placebo 2 tablets qhs (DRUG).
Who is sponsoring clinical trial NCT01040208?
This trial is sponsored by Sprout Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.